2月10日 - ** 制药商Nektar Therapeutics NKTR.O股价盘前上涨4.15%至37.94美元
** 该公司称其实验性湿疹药物rezpegaldesleukin有助于中度至重度湿疹患者在一年内保持病情好转
** 湿疹是一种慢性瘙痒性皮肤病
** 公司称，71% 和 83% 的患者在服用最高剂量的月剂量和季度剂量后，症状得到了控制；高达 30% 的患者皮肤得到了完全清除
** 称副作用主要是轻微的注射部位反应，没有新的安全问题；3.5%的患者因副作用停止治疗
** 计划开展更大规模的后期研究，争取在 2029 年获得批准；称该药物已获得 FDA 快速通道资格
** 2025 年 NKTR 增长约 203
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.